Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTITUDE-5: VRd induction followed by cilta-cel vs VRd followed by Rd in transplant-ineligible newly diagnosed multiple myeloma
jRCT2011210025Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 3, randomised trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival (PFS). Started Nov 2021; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2011210025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210025.